Carl Zeiss Meditec AG

CZMWY | OTC

Price Alert Chart Builder DCF Calculator

$40.23

+$0.02 (+0.05%)

At close: Nov 5, 2026, 3:25 PM ET

$40.40

+$0.17 (+0.42%)

Pre-market: Nov 5, 2026, 11:29 AM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+0.05%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

-0.9 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #385/1024 (Top 38%)

Full Analysis

Key Statistics

Market Data

Market Cap $3.52B

1D Range

39.87 40.45

52W Range

26.71 53.40

Valuation (TTM)

PE 20.64

PB 1.46

EV/EBITDA 9.32

Valuation (NTM)

Forward PE 24.16

Forward PEG 1.89

Price Target $0.00

Cash Flow

FCF Yield 8.7%

SBC Adj. FCF Yield 8.7%

SBC Impact N/A

Margins

Gross Margin 51.0%

Operating Margin 6.4%

FCF Margin 10.3%

Growth (CAGR)

Revenue 3Y | 5Y 8.4% | 11.1%

Dil EPS 3Y | 5Y -25.3% | -8.8%

FCF 3Y | 5Y 38.0% | -1.6%

Returns

ROA 0.0%

ROE 5.5%

ROIC 0.0%

Financial Health

Net Debt

Current Ratio 0.00

Interest Coverage 5.27

Dividends

Div Yield 1.57%

Payout Ratio 37.7%

FCF Payout Ratio 17.7%

All Key Statistics

Loading financial charts...

Profile

Carl Zeiss Meditec AG functions as a prominent global medical technology firm, conducting its operations across Germany, other European nations, the United States, and various Asian markets. Its busin...

Sector Healthcare

Industry Medical - Instruments & Supplies

Employees 5,784

IPO Date Aug 3, 2012

Website www.zeiss.com/meditec-ag/de/home.html

Fiscal Year n/a

Full Company Profile

Latest News

10 days ago · seekingalpha.com

Carl Zeiss Meditec: Why The Market Is Finally Recognizing The Recovery

Carl Zeiss Meditec has rebounded nearly 50% from its early 2026 lows, validating the recovery thesis after a severe medtech sector downturn. Despite a 40% earnings decline and 64% share price drop, CZMWY remains fundamentally sound, with established products, strong ownership, and resilience through downturns. I maintain a €65/share price target and rate CZMWY a 'Buy,' citing potential EBITA margin recovery to 15% and normalized EPS above €2.5/share post-2027.

3 months ago · seekingalpha.com

Carl Zeiss Meditec AG (CZMWY) Q3 2026 Earnings Call Transcript

Earnings

Next Earnings

Dec 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞